Data / Drug companies / Shilpa Pharma Lifesciences Limited
Shilpa Pharma Lifesciences Limited: 40 products in the FDA NDC directory, labeler code 82920
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Shilpa Pharma Lifesciences Limited (labeler code 82920) lists 40 products in the FDA National Drug Code Directory. By type: 40 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on August 28, 2026.
The request: Watch Shilpa Pharma Lifesciences Limited (FDA labeler code 82920): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 82920
- Products in commercial distribution
- 40
- Packages
- 50
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 7
- Earliest marketing start
- September 9, 2021
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 32 | 80% |
| Bulk ingredients for compounding | 8 | 20% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 40 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 40 | 100% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Erlotinib hydrochloride | 82920-200 | Powder | Bulk ingredients for compounding | August 28, 2026 |
| Ambroxol hydrochloride | 82920-717 | Powder | Bulk ingredients | May 10, 2026 |
| Semaglutide | 82920-505 | Powder | Bulk ingredients for compounding | April 30, 2026 |
| Liraglutide | 82920-504 | Powder | Bulk ingredients for compounding | April 30, 2026 |
| Sermorelin acetate | 82920-501 | Powder | Bulk ingredients for compounding | April 30, 2026 |
| Cyclophosphamide | 82920-503 | Powder | Bulk ingredients for compounding | April 12, 2026 |
| Nifedipine | 82920-502 | Powder | Bulk ingredients for compounding | April 12, 2026 |
| Sunitinib malate | 82920-037 | Powder | Bulk ingredients | September 27, 2023 |
| Tranexamic acid | 82920-045 | Powder | Bulk ingredients | May 29, 2023 |
| Prucalopride succinate | 82920-042 | Powder | Bulk ingredients | October 21, 2022 |
| Lenvatinib mesylate | 82920-036 | Powder | Bulk ingredients | August 15, 2022 |
| Axitinib | 82920-028 | Powder | Bulk ingredients | August 15, 2022 |
| Nifedipine | 82920-709 | Powder | Bulk ingredients for compounding | August 11, 2022 |
| Cyclophosphamide | 82920-708 | Powder | Bulk ingredients | August 11, 2022 |
| Gemcitabine hydrochloride (process-2) | 82920-706 | Powder | Bulk ingredients | August 11, 2022 |
| Pirfenidone | 82920-705 | Powder | Bulk ingredients | August 11, 2022 |
| Oxaliplatin | 82920-704 | Powder | Bulk ingredients | August 11, 2022 |
| Temozolomide | 82920-703 | Powder | Bulk ingredients | August 11, 2022 |
| Irinotecan hydrochloride trihydrate | 82920-702 | Powder | Bulk ingredients | August 11, 2022 |
| Gemcitabine hydrochloride | 82920-701 | Powder | Bulk ingredients | August 11, 2022 |
| Abiratrone acetate | 82920-040 | Powder | Bulk ingredients | August 11, 2022 |
| Tranexamic acid | 82920-038 | Powder | Bulk ingredients for compounding | August 11, 2022 |
| Ibrutinib | 82920-031 | Powder | Bulk ingredients | August 11, 2022 |
| Dimethyl fumarate | 82920-027 | Powder | Bulk ingredients | August 11, 2022 |
| Clofarabine | 82920-024 | Powder | Bulk ingredients | August 11, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.